National Coverage Analysis (NCA)

Positron Emission Tomography (FDG) for Brain, Cervical, Ovarian, Pancreatic, Small Cell Lung, and Testicular Cancers

CAG-00181N

Expand All | Collapse All

Contacts

David Dolan
David.Dolan@cms.hhs.gov
410-786-3365
Lead Analysts
Lead Medical Officers

History of Considerations

History Title ID
Original Consideration Positron Emission Tomography (FDG) for Brain, Cervical, Ovarian, Pancreatic, Small Cell Lung, and Testicular Cancers CAG-00181N You are here
First reconsideration Positron Emission Tomography (FDG) for Solid Tumors CAG-00181R View
Second reconsideration Positron Emission Tomography (FDG) for Cervical Cancer CAG-00181R2 View
Third reconsideration Positron Emission Tomography for Initial Treatment Strategy in Solid Tumors and Myeloma CAG-00181R3 View
Fourth reconsideration Positron Emission Tomography (FDG) for Solid Tumors CAG-00181R4 View